cevimeline (Evoxac)

RN refers to (cis)-isomer

Also Known As:

Evoxac; 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine; AF 102B; AF 102B, (cis-(+))-isomer; AF 102B, (trans)-isomer; AF-102B; AF102B; FKS 508; FKS-508; SNI 2011; SNI-2011; cevimeline hydrochloride

Networked: 102 relevant articles (22 outcomes, 20 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - cevimeline: 102
- Bridged-Ring Heterocyclic Compounds
  - Quinuclidines: 20
    - cevimeline: 102
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - cevimeline: 102

Experts

1.	Arisawa, Hirohiko: 4 articles (01/2002 - 01/2002)
2.	Fukui, Kenji: 4 articles (01/2002 - 01/2002)
3.	Masunaga, Hiroaki: 4 articles (01/2002 - 01/2002)
4.	Chambers, Mark S: 3 articles (08/2012 - 07/2007)
5.	Fujise, Nobuaki: 3 articles (01/2002 - 01/2002)
6.	Deng, Chao: 2 articles (01/2022 - 01/2020)
7.	Lian, Jiamei: 2 articles (01/2022 - 01/2020)
8.	Brennan, Michael T: 2 articles (01/2021 - 03/2007)
9.	Mercadante, Valeria: 2 articles (01/2021 - 01/2017)
10.	Soares-Weiser, Karla: 2 articles (01/2018 - 11/2004)

Related Diseases

1.	Xerostomia 01/01/2002 - "In these studies, cevimeline 30mg three times daily increased salivary flow and improved the symptoms of xerostomia in a significantly higher percentage of patients compared with placebo. " 11/19/1997 - "These results indicate that SNI-2011 may be useful in the treatment of xerostomia because of its long-lasting sialogogic action." 11/01/1994 - "These results suggest that SNI-2011 could be useful in the treatment of xerostomia in patients with Sjögren's syndrome." 04/01/2008 - "The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study." 06/10/2002 - "We evaluated the safety and efficacy of cevimeline in the treatment of xerostomia in patients with Sjögren syndrome. "
2.	Dry Eye Syndromes (Dry Eye Syndrome) 01/01/2008 - "Other symptoms, such as dry eye symptoms and overall dryness, also improved to a significantly greater extent with cevimeline than with placebo. " 07/01/2004 - "These results indicate that cevimeline, 20 mg three times daily, is safe and effective in improving symptoms of dry eye in patients with SS. " 07/28/2010 - "Two placebo-controlled trials found that cevimeline was associated with improvement in dry mouth (66%-76% vs 35%-37% in the placebo group) and dry eye (39%-72% vs 24%-30%). " 07/01/2004 - "In this study, the efficacy of cevimeline in improving symptoms of dry eye was examined. " 07/01/2004 - "Additional studies, with larger patient populations, are needed to further assess the effectiveness of cevimeline for dry eye."
3.	Sjogren's Syndrome (Sjogren Syndrome) 01/01/2008 - "Moreover, cevimeline significantly improved the salivary flow rate in patients with Sjogren's syndrome. " 01/01/2008 - "Increased salivary flow was maintained in the longer term with cevimeline in patients with Sjogren's syndrome and symptoms of dry mouth, according to the results of an open-label 52-week study. " 01/01/2008 - "Oral cevimeline 30 mg three times daily was generally well tolerated in patients with Sjogren's syndrome, with many of the most commonly reported adverse events reflecting the pharmacological action of the drug." 01/01/2008 - "Several well designed placebo-controlled trials demonstrated that 4-12 weeks' therapy with cevimeline 30 mg three times daily improved symptoms of dry mouth in patients with Sjogren's syndrome. " 01/01/2008 - "Cevimeline is an orally administered muscarinic receptor agonist that is indicated for the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. "
4.	Xerophthalmia 04/01/2008 - "Cevimeline hydrochloride, a specific agonist of the M3 muscarinic receptor, is beneficial in the treatment of symptoms of xerostomia and xerophthalmia associated with Sjögren's syndrome (SS). " 11/01/1998 - "We investigated effects of (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride), a rigid analogue of acetylcholine, on saliva and tear secretions in rats and mice to evaluate its therapeutical efficacy for xerostomia and xerophthalmia in patients with Sjogren's syndrome and X-ray exposure in the head and neck. "
5.	Head and Neck Neoplasms (Head and Neck Cancer) 12/01/2007 - "A total of 255 adults with head-and-neck cancer who had received more than 40 Gy of radiation 4 months or more before entry and had clinically significant salivary gland dysfunction received cevimeline hydrochloride 45 mg t.i.d. " 12/01/2007 - "To assess the safety of long-term cevimeline treatment of radiation-induced xerostomia in patients with head-and-neck cancer; and to assess the efficacy of cevimeline in these patients. " 07/15/2007 - "Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer." 07/15/2007 - "To study the efficacy and safety of cevimeline in two double-blind trials (Studies 003 and 004) enrolling patients with head and neck cancer in whom xerostomia developed after radiotherapy. " 01/01/2021 - "For patients with head and neck cancer, oral pilocarpine and oral cevimeline, acupuncture, or transcutaneous electrostimulation may be offered after radiation therapy.Additional"

Related Drugs and Biologics

1.	cevimeline (Evoxac)
2.	Pilocarpine (Ocusert)
3.	Cholinergic Agents (Cholinergics)
4.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
5.	xanomeline
6.	Quinuclidines
7.	Antipsychotic Agents (Antipsychotics)
8.	Olanzapine (Zyprexa)
9.	Immunologic Factors (Immunomodulators)
10.	Tacrine (Cognex)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Radiotherapy
4.	Intravenous Administration
5.	Palliative Care (Palliative Therapy)